Latest KFF Health News Stories
An Arm and a Leg: John Green vs. Johnson & Johnson (Part 2)
The high price of lifesaving tuberculosis drugs makes them inaccessible to many who need them most. On this episode of “An Arm and a Leg,” hear how a decades-long global fight to reform drug patents is helping to lower the cost.
Jimmy Carter se enfrentó al horrible gusano de Guinea cuando nadie más lo hizo. Y ganó
El Centro Carter informó que en 2022, solo hubo 13 casos humanos registrados de la enfermedad, un número provisional que se confirmará oficialmente, probablemente este mes.
Jimmy Carter Took on the Awful Guinea Worm When No One Else Would — And Triumphed
The effort to end Guinea worm disease relies almost entirely on changes in people’s behavior. There is no cure, no vaccination. When the 39th president of the United States left office, Jimmy Carter campaigned to eradicate the disease.
To Stem the Spread of Monkeypox, Health Departments Tap Into Networks of Those Most at Risk
Although the disease is currently spreading almost exclusively among men who have sex with men, some cases are turning up in other populations — and that number is likely to grow if public health officials don’t effectively nip the outbreak in the bud.
Igual que con covid, atraso en pruebas y vacunas para la viruela del simio
Los casos de la viruela del simio siguen aumentando, pero la respuesta sanitaria es lenta: escasean las pruebas y las dosis de la vacuna que puede prevenir la infección.
Vaccine and Testing Delays for Monkeypox Echo Failures in Early Covid Response
Public health officials say monkeypox is not as dangerous as covid and can be handled well with current treatments and if those at risk use caution. But the rollout of vaccines has been slow and led to angst among some at-risk people.
Lo que debes saber sobre la viruela del simio
Generalmente es una enfermedad leve, pero puede ser grave o incluso mortal para las personas inmunodeprimidas, embarazadas, fetos o recién nacidos, mujeres lactantes, niños pequeños y personas con enfermedades de la piel, como eccema.
What You Need to Know About Monkeypox
For now, monkeypox poses a low risk to the U.S. public, but it could become a problem if the spread is left unchecked. Here’s what everyone should know about it.
KHN’s ‘What the Health?’: The Invisible Pandemic
Covid cases are again climbing, but you wouldn’t know it from the behavior of public health and elected officials, much less the general public, all of whom seem to want to put the pandemic in the rearview mirror. Meanwhile, the fallout over the leaked Supreme Court draft opinion on abortion continues even as the Senate fails — again — to muster the votes to write abortion rights into law. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Alice Miranda Ollstein of Politico, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
Travel in the Time of Covid: Getting There Is Easy — It’s Getting Home That’s Hard
The part of my London visit that I didn’t plan was testing positive for the coronavirus. I couldn’t get back to the U.S., but the U.K. didn’t care what I did or where I went.
Which Companies Aren’t Exiting Russia? Big Pharma
U.S. and global drug manufacturers invested in Russia’s sizable pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion. Not everyone agrees.
Hospitales le piden a Santa suministros: falta de todo, desde sillas de ruedas hasta jeringas
En otra consecuencia de la crisis de la cadena de suministro global, hospitales que gestionan los picos de casos de covid durante las Fiestas y a todos sus otros pacientes se están quedando sin suministros básicos para atenderlos
Never Mind Toys, It’s Time to Ask Santa for Crutches and Catheters
As hospitals juggle holiday covid surges and all their other patients, the global supply chain crisis has left them short of critical supplies.
Todo lo que hay que saber sobre omicron y las otras variantes del coronavirus
La variante omicron, conocida oficialmente como B.1.1.529, apareció en noviembre en varios países del sur de África. Las alarmas saltaron en todo el mundo cuando los funcionarios de salud pública de Sudáfrica vieron que empezaba a superar a delta, la cepa dominante hasta ahora.
Omicron and Other Coronavirus Variants: What You Need to Know
This new variant has set off alarm bells in the public health community, but much remains to be learned about it.
KHN’s ‘What the Health?’: Delta Blues
Covid is back with a vengeance, with some people clamoring for booster shots while others harden their resistance to getting vaccinated at all. Meanwhile, the Food and Drug Administration is pushing hard on drugmaker Pfizer’s request to upgrade the emergency authorization for its vaccine and give it final approval. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest their favorite health policy stories of the week they think you should read, too.
Unraveling the Mysterious Mutations That Make Delta the Most Transmissible Covid Virus Yet
Scientists are trying to piece together why the delta variant so readily infects unvaccinated Americans, spewing 1,000 times more virus particles.
Delta ha mantenido algunas de las mutaciones más exitosas encontradas en variantes anteriores, pero también contiene nuevos cambios genéticos que le permiten propagarse dos veces más rápido.
Analysis: Necessary or Not, Covid Booster Shots Are Probably on the Horizon
In today’s pharmaceutical universe, a simple “safe and effective” determination by the Food and Drug Administration to approve a drug can be manipulated to sell products of questionable value. And drugmakers can profit handsomely.
Novavax’s Effort to Vaccinate the World, From Zero to Not Quite Warp Speed
Novavax is a vaccine company that, despite $2 billion in new federal and international funding, still hasn’t come through with a licensed covid vaccine. It hopes it can still help to fight the global covid scourge, but will it deliver?
